PF-219,061
Encyclopedia
PF-219,061 is a drug developed by Pfizer
which acts as a potent and highly selective
agonist
for the dopamine
D3 receptor
. It is under development as a potential medication for the treatment of female sexual dysfunction.
Pfizer
Pfizer, Inc. is an American multinational pharmaceutical corporation. The company is based in New York City, New York with its research headquarters in Groton, Connecticut, United States...
which acts as a potent and highly selective
Functional Selectivity
Functional selectivity is the ligand-dependent selectivity for certain signal transduction pathways in one and the same receptor. This can be present when a receptor has several possible signal transduction pathways...
agonist
Agonist
An agonist is a chemical that binds to a receptor of a cell and triggers a response by that cell. Agonists often mimic the action of a naturally occurring substance...
for the dopamine
Dopamine
Dopamine is a catecholamine neurotransmitter present in a wide variety of animals, including both vertebrates and invertebrates. In the brain, this substituted phenethylamine functions as a neurotransmitter, activating the five known types of dopamine receptors—D1, D2, D3, D4, and D5—and their...
D3 receptor
Receptor (biochemistry)
In biochemistry, a receptor is a molecule found on the surface of a cell, which receives specific chemical signals from neighbouring cells or the wider environment within an organism...
. It is under development as a potential medication for the treatment of female sexual dysfunction.
See also
- ABT-670ABT-670ABT-670 is a drug which acts as a potent, orally bioavailable dopamine agonist selective for the D4 subtype, which was developed as a possible treatment for erectile dysfunction, although its current uses are limited to scientific research.-See also:...
- ABT-724ABT-724ABT-724 is a drug which acts as a dopamine agonist, and is selective for the D4 subtype. It was developed as a possible drug for the treatment of erectile dysfunction, although poor oral bioavailability means alternative drugs such as ABT-670 may be more likely to be developed commercially...
- CabergolineCabergolineCabergoline , an ergot derivative, is a potent dopamine receptor agonist on D2 receptors. In vitro, rat studies show cabergoline has a direct inhibitory effect on pituitary lactotroph cells...
- BremelanotideBremelanotideBremelanotide is a compound under drug development by Palatin Technologies as a treatment for hemorrhagic shock and reperfusion injury...
- FlibanserinFlibanserinFlibanserin is a drug that was investigated by Boehringer Ingelheim as a novel, non-hormonal treatment for pre-menopausal women with Hypoactive Sexual Desire Disorder . Development was terminated in October 2010 following a negative report by the U.S...
- IntrinsaIntrinsaIntrinsa is a testosterone patch by Procter & Gamble designed to treat Female Sexual Dysfunction .-Background:FSD covers at least four different conditions: problems with desire, arousal, achieving orgasm, and genital pain. The patch aims to increase libido in women...
- Melanotan IIMelanotan IIMelanotan II developed at the University of Arizona is a synthetic analog of the naturally occurring melanocortin peptide hormone alpha-melanocyte stimulating hormone that in usage has been shown to have melanogenesis and aphrodisiac effects in preliminary studies and clinical trials...
- PramipexolePramipexolePramipexole is a non-ergoline dopamine agonist indicated for treating early-stage Parkinson's disease and restless legs syndrome...
- TiboloneTiboloneTibolone is a synthetic steroid hormone drug, which is fairly non-selective in its binding profile, acting as an agonist at all five of the Type I steroid hormone receptors. It is used mainly for treatment of endometriosis, as well as hormone replacement therapy in post-menopausal women...
- UK-414,495UK-414,495UK-414,495 is a drug developed by Pfizer for the treatment of female sexual arousal disorder. UK-414,495 acts as a potent, selective inhibitor of the enzyme neutral endopeptidase, which normally serves to break down the neuropeptide VIP...